Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.60 |
| ▸ | CTSS | P25774 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6962076 | 0.88 | AAK1 (0.59) | AAK1CTSSMEN1KMT2ANPC1 | |
| SCHEMBL6962080 | 0.88 | AAK1 (0.59) | AAK1CTSSMEN1KMT2ANPC1 | |
| SCHEMBL6961702 | 0.86 | AAK1 (0.57) | AAK1CTSSMEN1KMT2ANPC1 | |
| SCHEMBL28199963 | 0.85 | MEN1 (0.52) | AAK1CTSSMEN1KMT2ANPC1 | |
| SCHEMBL28199962 | 0.85 | MEN1 (0.52) | AAK1CTSSMEN1KMT2ANPC1 | |
| SCHEMBL15721183 | 0.85 | MEN1 (0.52) | AAK1CTSSMEN1KMT2ANPC1 | |
| SCHEMBL15698608 | 0.83 | MEN1 (0.54) | AAK1CTSSMEN1KMT2ANPC1 | |
| SCHEMBL16974942 | 0.83 | KMT2A (0.51) | AAK1CTSSMEN1KMT2ANPC1 | |
| SCHEMBL31152353 | 0.81 | MEN1 (0.49) | AAK1CTSSMEN1KMT2ANPC1 | |
| SCHEMBL16970626 | 0.81 | MEN1 (0.52) | AAK1CTSSMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | AAK1, NCK1, ADCK1 | AAK1 1/4885CTSS 4146/4885MEN1 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.